Company intelligence / Profile preview
Nielsen BioSciences, Inc.
San Diego, California, United Statesnielsenbio.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Phase 3
01
Overview
Nielsen BioSciences markets two FDA-approved skin test antigens—CANDIN® and SPHERUSOL®—for assessing cell-mediated immunity to Candida albicans and Coccidioides immitis, respectively. The company is conducting a Phase 3 clinical trial evaluating CANDIN® as a treatment for common warts caused by HPV. These programs leverage the activation of cell-mediated immune responses to diagnose or potentially treat infectious diseases.
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Biological products (antigen-based skin test antigens)Immunotherapies (cell-mediated immune response activators)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Nielsen BioSciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nielsen BioSciences, Inc..